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7Équipe Labellisée Ligue Nationale Contre le Cancer, F-91405 Orsay, France, 8INSERM U932, RT2Lab Team,
Translational Research Department, PSL Research University, Institut Curie, F-75005 Paris, France, 9CNRS
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ABSTRACT
ERG family proteins (ERG, FLI1 and FEV) are a sub-
family of ETS transcription factors with key roles
in physiology and development. In Ewing sarcoma,
the oncogenic fusion protein EWS-FLI1 regulates
both transcription and alternative splicing of pre-
messenger RNAs. However, whether wild-type ERG
family proteins might regulate splicing is unknown.
Here, we show that wild-type ERG proteins asso-
ciate with spliceosomal components, are found on
nascent RNAs, and induce alternative splicing when
recruited onto a reporter minigene. Transcriptomic
analysis revealed that ERG and FLI1 regulate large
numbers of alternative spliced exons (ASEs) en-
riched with RBFOX2 motifs and co-regulated by this
splicing factor. ERG and FLI1 are associated with RB-
FOX2 via their conserved carboxy-terminal domain,
which is present in EWS-FLI1. Accordingly, EWS-FLI1
is also associated with RBFOX2 and regulates ASEs
enriched in RBFOX2 motifs. However, in contrast
to wild-type ERG and FLI1, EWS-FLI1 often antag-
onizes RBFOX2 effects on exon inclusion. In particu-
lar, EWS-FLI1 reduces RBFOX2 binding to the ADD3
pre-mRNA, thus increasing its long isoform, which
represses the mesenchymal phenotype of Ewing sar-
coma cells. Our findings reveal a RBFOX2-mediated
splicing regulatory function of wild-type ERG family
proteins, that is altered in EWS-FLI1 and contributes
to the Ewing sarcoma cell phenotype.
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INTRODUCTION
ERG (E-26 transformation specific-related gene) family
proteins (ERG, FLI1 and FEV) belong to the larger fam-
ily of ETS transcription factors (TFs), that is one of the
largest families of TFs in metazoans and is defined by a
highly conserved DNA-binding ETS domain (1). Accord-
ing to the current model, ERG family proteins act as canon-
ical TFs, binding to specific DNA sequences in promot-
ers and enhancers through their ETS domain and regulat-
ing expression of their target genes (2). Our recent find-
ings have led us to challenge this view. Indeed, we reported
that in addition to their role in transcription, ERG fam-
ily proteins also impact gene expression through regula-
tion of mRNA decay (3). However, whether ERG proteins
may be involved in additional steps of the mRNA life is
unknown.
ERG family genes are implicated in oncogenic gene fu-
sions due to translocations that typify several cancers. These
include prostate cancers (4), myeloid leukemias (5) and Ew-
ing sarcoma (6), a highly aggressive bone and soft tissue
tumor. Because they consistently include the C-terminal
half of the ERG protein, which contains the ETS DNA-
binding domain, ERG fusions have mostly been studied as
oncogenic TFs. Indeed, these fusions acquire specific tran-
scriptional properties that are not shared by wild-type (wt)
ERG factors. For instance, EWS-FLI1, the primary onco-
genic fusion of Ewing sarcoma gains the ability to bind
and epigenetically convert silenced GGAA microsatellites
into active enhancers (7,8). In addition to its transcrip-
tional activity, EWS-FLI1 has been shown to influence al-
ternative splicing of pre-messenger RNAs (pre-mRNAs)
through interactions with core components of the spliceo-
some or through regulation of RNA polymerase II elon-
gation rate (9–12). Because of the functions of EWS in
various stages of mRNA metabolism, including splicing
(13,14), the splicing activity of EWS-FLI1 has been at-
tributed to its EWS moiety. Indeed, wild-type ERG fam-
ily proteins have not been shown to be involved in splicing
regulation.
Beyond regulating pre-mRNA synthesis, TFs can also af-
fect downstream steps of gene expression. In particular, a
number of studies have reported cases of TFs involved in
pre-mRNA splicing regulation (15). However, these studies
almost exclusively describe indirect mechanisms, in which
TFs impact pre-mRNA splicing by modification of RNA
polymerase II elongation rate, recruitment of transcrip-
tional coactivators that affect splicing, or modulation of the
expression of direct splicing regulators (e.g. core spliceo-
some components and other splicing factors) (16). More
recently, it was shown that some TFs bind directly to pre-
mRNA and control alternative splicing via unknown yet di-
rect mechanisms (17).
In this study, we identify and characterize a novel non-
transcriptional function of wild-type ERG family proteins
in alternative splicing of pre-mRNAs. While wild-type ERG
and FLI1 proteins cooperate with the splicing regulator
RBFOX2, EWS-FLI1 represses a subset of the RBFOX2-
dependent mesenchymal splicing program, including an iso-




Constructs encoding human FLI1, ERG and FEV have
been described elsewhere (3). Open reading frames (ORF)
encoding human RBFOX1, RBFOX2 and EWS were
obtained as pDONR223 from the human ORFeome v5.1
(Center of Cancer Systems Biology (CCSB), Dana-Farber
Cancer Institute (DFCI)). Isolated domains and deletion
variants of ERG, and EWS and ERG fusions were inserted
into pDONR223 by Gateway cloning (Invitrogen) using
specific primers flanked in 5′ by the following AttB1 and
AttB2 Gateway sites (Forward: 5′-GGGGACAACTTT
GTACAAAAAAGTTGGC(ATG)-3′(AttB1); Reverse:
5′-GGGGACAACTTTGTACAAGAAAGTTGA-3′
(AttB2)). Inserts were transferred from the pDONR223
into destination vectors (N-terminal tags): pDEST1899
(FLAG), pDEST1899-MS2-CP (FLAG-MS2-CP Nter
tag), pDEST475 (HA) (kind gifts of James L. Hartley and
Dominic Esposito, SAIC-Frederick Inc.), and Gateway
modified pGEX-2TK (GST) (kind gift from Pascal Braun,
CCSB, Dana-Farber Cancer Institute). pDEST1899-
FLAG Erg ORFs were subcloned in the pN-MS2-CP
(MS2 Nt) described in (19), following classical cloning
procedures. All constructs were verified by sequencing.
Cell lines
Cell lines were obtained from American Type Culture
Collection (ATCC) and were routinely checked for my-
coplasma. Human Umbilical Vein Endothelial Cells (HU-
VECs) were obtained from Lonza. Ewing sarcoma cell
line A673/TR/shEF (also called ASP14) was generated
as previously described (20) and MHH-ES1 has been or-
dered from the DSMZ collection. All cell lines, except for
HL-60 and HUVECs were cultured at 37◦C, in 5% CO2
with DMEM (Gibco) supplemented with 10% FBS (Euro-
bio) and 1% antibiotics (penicillin and streptomycin, P/S
(Gibco)). HL-60 were cultured in RPMI (Gibco), 10% FCS
and 1% P/S. HUVECs were grown at 37◦C, in endothelial
growth medium (EGM-2, Lonza, UK) and passages 2–7
were used for the study.
Induction of EWS-FLI1 specific shRNA was performed
by adding 1 g/ml of doxycycline (DOX) in the medium
ex-tempo. For reversion studies, doxycycline was removed
after 7 days and cells were washed three times to stop the
shRNA induction.
DNA and siRNA transfection
Plasmids were transfected in HeLa cells with the Lipofec-
tamine 2000 Transfection System according to the man-
ufacturers’ protocol (Thermo Fisher Scientific) and in
HEK293 cells using the phosphate-calcium method, un-
less otherwise stated. Cells were collected 36–48 h post-
transfection.
Transfection of siRNAs (see sequences in Supplementary
Table S13) was performed using Lipofectamine RNAiMAX
Reagent (Thermo Fisher Scientific) or JetPRIME (Poly-
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transfections in HUVECs were performed using the Gen-
eTrans 2 (MoBiTec) reagents according to the manufac-
turer’s protocol. Cells were collected 48 or 72 h post-
transfection.
Western blot
Cells were washed once with cold PBS and scraped on ice
with lysis buffer (20 mM Tris–HCl pH 8; 1% NP40; 150
mM NaCl) supplemented with protease inhibitor cocktail
(Sigma). Protein lysates were quantified using Bradford pro-
tein assay (BioRad). Alternatively, total cell extracts were
prepared by lysing cells directly into Laemmli buffer. Pro-
teins extracts were separated by sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE) electrophoresis and trans-
ferred onto nitrocellulose membrane. Membranes were in-
cubated with primary antibodies followed by horseradish
peroxidase-conjugated anti-IgG. Proteins were detected us-
ing enhanced chemiluminescence (Pierce) and images were
acquired with ChemiDoc™ Gel Imaging System (Bio-Rad).
Quantifications were performed using the ImageJ software.
Primary antibodies are listed in Supplementary Table S13.
MS2-based tethering assay
MS2-based tethering assays were performed using HeLa
cells co-transfected with control MS2-CP or various MS2-
CP-tagged constructs, together with SMN2-MS2 minigene
(21). Reverse transcription (RT)-PCR amplifications were
performed (see below) using forward and reverse primers
of SMN2-MS2 minigene (See Supplementary Table S13).
Protein complementation assay
ORFs corresponding to RBFOX2 and ERG full-length or
ERG lacking the CTAD region were cloned in pSPICA-N1
or pSPICA-N2 destination vectors containing the GLucN1
and GLucN2 fragments of the Gaussia princeps luciferase,
respectively (22). HEK293T cells were cultured in 24-
well plates and transfected with 500 ng of the appropri-
ate constructs (GLucN1 + GLucN2) using polyethylen-
imine (PEI). The DNA/PEI ratio (mass:mass) was 1:3. Cell
medium was removed 24 h post-transfection. Two hundreds
L of the Renilla Luciferase Assay Lysis Buffer (Renilla Lu-
ciferase Assay System, Promega) were added in each well
and cell lysis was performed under vigorous shaking for 20
min. Thirty microliters of cell lysates were plated in 96-well
White Flat Bottom plates in triplicates. Luminescence was
measured by auto-injecting 30 l per well of Renilla Lu-
ciferase substrate using a Centro XS3 LB 960 luminometer
(Berthold Technologies; 1 sec delay time; 10 s integration
time).
Subcellular fractionation
HeLa (treated or not for 2 h with 5 M Actinomycin D)
or HL-60 cells were washed with cold PBS, harvested and
lysed with CLB buffer [Cytoplasmic Lysis Buffer; 10 mM
Tris–HCl pH 7.9, 340 mM Sucrose, 3 mM CaCl2, 0.1 mM
EDTA, 2 mM MgCl2 1 mM DTT, 0.5% NP40, cOmplete
Protease Inhibitor Cocktail (Roche) and Halt Phosphatase
Inhibitor Cocktail (Thermo Fisher Scientific)] on ice for 5
min. The cytoplasmic fraction was removed by centrifuga-
tion at 3500 × g for 15 min at 4◦C. The pellet was washed
several times with CLB wash buffer (CLB buffer without
NP40) and lysed with NLB buffer [Nuclear Lysis Buffer; 20
mM HEPES pH 7.9, 10% glycerol, 3 mM EDTA, 150 mM
KOAc, 1.5 mM MgCl2, 1 mM DTT, 0.1% NP40, cOmplete
Protease Inhibitor Cocktail (Roche), Halt Phosphatase In-
hibitor Cocktail and Protector RNase Inhibitor (Roche)].
Soluble and Chromatin/HMW fractions were separated by
centrifugation at 15 000 × g for 30 min at 4◦C. The pellet
was washed several times with NLB washing buffer (NLB
buffer without NP40), centrifuged at 3500 × g for 5 min
and lysed with NIB buffer (Nuclease Incubation Buffer;
150 mM HEPES pH 7.9, 10% Glycerol, 150 mM KOAc,
1.5 mM MgCl2, 1 mM DTT, cOmplete Protease Inhibitor
Cocktail and Halt Phosphatase Inhibitor Cocktail). Next,
the lysate was divided into two equal portions, one of which
was treated with 10 g/ml of RNase A (Thermo Fisher Sci-
entific) for 30 min at RT. Then, lysates were centrifuged
at 20 000 × g for 30 min and supernatants were recov-
ered as the RNA-associated chromatin fraction. The pellets
were incubated at 25◦C on a rotator with 5 U/l of Ben-
zonase (Sigma) to solubilize the DNA-associated fraction.
Cell fractions were then analyzed by SDS-PAGE.
Immunoprecipitation
For endogenous co-immunoprecipitation, HeLa cells were
lysed in IPLS buffer [ImmunoPrecipitation Law Salt; 50
mM Tris–HCl pH 7.5, 0.5 mM EDTA pH 8, 0.5% NP-
40, 10% glycerol, 120 mM NaCl, cOmplet Protease In-
hibitors (Roche) and Halt Phosphatase Inhibitors (Thermo
Scientific)]. Lysates were incubated with Protein G mag-
netic beads (Millipore) for 1 h at 4◦C for preclearing and
incubated at 37◦C for 30 min with or without RNase A
(200 g/ml) (Thermo Scientific). Then, lysates were in-
cubated for 2 h at 4◦C with Protein G magnetic beads
(Millipore) and anti-ERG antibody or rabbit anti-IgG an-
tibody (Santa Cruz). Beads were washed 4 times with
IPLS buffer. Immunoprecipitates were boiled in Laemmli
buffer and analyzed by SDS-PAGE and Western blot ac-
cording to standard procedures and developed with the
ECL detection kit (GE Healthcare Bio-Sciences, Uppsala,
Sweden).
For co-immunoprecipitation of overexpressed proteins,
HEK293 cells overexpressing ERG-FLAG or deletion vari-
ants of ERG and HA/MYC-tagged proteins were lysed in
IPLS buffer. Lysates were then incubated with anti-FLAG
M2 magnetic beads (Sigma-Aldrich) for 2 h at 4◦C, washed
3 times with IPLS lysis buffer, twice with IPMS buffer (Im-
munoPrecipitation Medium Salt: IPLS with 500 mM NaCl)
and twice with IPLS buffer. Immunoprecipitates were either
boiled in Laemmli buffer and analyzed by SDS-PAGE or
selectively eluted from anti-FLAG M2 magnetic beads by
3 successive elutions using 3XFLAG peptide (0.2 mg/ml in
IPLS buffer, 3 times 20 min at 4◦C) (ApexBio). Eluates were
boiled in Laemmli and analyzed by SDS-PAGE and west-
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RT-PCR/qPCR
Total RNA was isolated using the Nucleospin II kit
(Macherey-Nagel) and reverse-transcribed using the High-
Capacity cDNA Reverse Transcription kit (Applied Biosys-
tems). Next, cDNA molecules were amplified by PCR using
the AmpliTaqGold DNA Polymerase kit with Gold Buffer.
One g of template total RNA was used for each reaction.
The resulting cDNA was diluted between 10- and 100-fold,
depending on the abundance of targets. Between 1 and 3 l
of diluted cDNA were used for PCR/qPCR amplifications.
Oligonucleotides were purchased from MWG Eurofins Ge-
nomics or Eurogentec (Supplementary Table S13). PCR re-
actions were loaded on 2% agarose gel electrophoresis with
SYBR Safe DNA Gel Stain (1/10 000, Invitrogen). Gels
were observed and photographed on a UV lamp and images
were analyzed by densitometry using the ImageJ software.
All Quantitative PCR reactions were performed on
ABI/PRISM 7500 instrument and analyzed with 7500 sys-
tem SDS software. The amplification cycle was composed
of an incubation at 50◦C for 2 min, followed by an initial
denaturation step at 95◦C for 10 min, 45 cycles at 95◦C for
10 s and 60◦C for 45 s. HPLC-purified oligonucleotides were
purchased from MWG Eurofins Genomics or Eurogentec.
Primer specificities were evaluated in silico using a blast ho-
mology search and assessed post-amplification by exami-
nation of the melt curve. Primer efficiencies were evaluated
by the PCR standard curve method and only primers with
>98% efficiency were used. Experiments were carried out in
triplicate for each data point and final results are presented
as average of at least three biological replicates. Relative
quantification of targets, normalized to an endogenous con-
trol, was performed using the comparative 2–Ct method.
Using this method, we obtained the fold changes in gene
expression or enrichment, normalized to an internal con-
trol (for gene expression levels) or to input (for RIP exper-
iments). Error bars indicate SD. Primers used are listed in
Supplementary Table S13.
RNA-immunoprecipitation-qPCR analysis
Dynabeads Protein G (ThermoFisher Scientific) were in-
cubated with anti-RBFOX2 antibody (A300-864A, Bethyl
Laboratories), anti-ERG antibody (ab133264, Abcam) or
normal rabbit IgG (Santa Cruz) at 4◦C overnight with rota-
tion. Before cell harvesting, RNA–protein complexes were
crosslinked with 1% formaldehyde (incubation at RT for 10
min) and crosslink reaction was quenched using 125 mM
glycine for 5 min at RT. Cells were washed twice with ice-
cold PBS before harvesting and pelleted by centrifugation
(4◦C, 5 min, 800 × g). Cells were resuspended in 1 ml RIPA
(Sigma) with Complete Protease Inhibitor Cocktail (Sigma)
at 1× concentration and 1 l RNAse inhibitor (RNase-
OUT, Thermo Fisher Scientific). Cell lysates were sonicated
for 5 min. Supernatant was collected after centrifugation at
4◦C for 10 min (10 000 × g). An aliquot was used for RNA
input and was treated with proteinase K before RNA ex-
traction with TRIzol Reagent (Thermo Fisher Scientific).
For immunoprecipitation, 400 g of protein were incubated
with antibody-loaded Dynabeads overnight with rotation
at 4◦C. Supernatant was removed and beads were washed
twice with RIPA buffer before RNA-protein complex elu-
tion by incubation with elution buffer (Tris–HCl pH 8 100
mM; Na2-EDTA 10 mM; 1% SDS in H2O) 3 min at 90◦C.
Proteins were digested with proteinase K treatment and
RNA was extracted with TRIzol Reagent (ThermoFisher
Scientific) for RT-qPCR analysis.
RNA sequencing and data processing
EWS-FLI1-dependent splicing events were identified by
comparing doxycycline-untreated versus doxycycline-
treated A673/TR/shEF cells. ERG-, FLI1 or RBFOX2-
dependent splicing events were identified by comparing
cells treated with siCTRL or with the corresponding
siRNA. RNA was isolated as described above and sample
integrity was evaluated using a Bioanlayzer instrument
(Agilent). Only samples with RNA Integrity Number above
9 were used. Libraries were performed using the TruSeq
Stranded mRNA Library Preparation Kit. Equimolar
pools of libraries were sequenced on a Illumina HiSeq
2500 machine using paired-end reads and High Output
run mode allowing 200 million raw reads per sample. Raw
reads were mapped to the human reference genome hg19
using the STAR aligner (v.2.5.0a) (23). PCR-duplicated
reads and low mapping quality reads (MQ<20) were
removed using Picard tools and SAMtools, respectively.
We next used rMATS (v3.0.9) (24), an event-based tool,
to identify differentially spliced events using RNA-seq
data. Five distinct alternative splicing events were analyzed
using rMATS: skipped exons (SE), alternative 3′ splice
sites (A3SS), alternative 5′ splice sites (A5SS), mutually
exclusive exons (MXE) and retained introns (RI). Briefly,
rMATS uses a count-based model, to calculate percent of
spliced-in (PSI) value among replicates, using both spliced
reads and reads that mapped to the exon body. We used
three different thresholds to identify differentially spliced
events between two groups: each splicing event has to be (i)
supported by at least 15 unique reads, (ii) |PSI| > 10%;
(iii) FDR < 0.05. For RT-qPCR validation, we choose a
set of alternative splicing events with PSI values spread
across a wide range. Events were selected from a list of
events with >50 reads supporting the event in at least one
condition (to allow detection by RT-PCR).
Gene expression analysis was performed as follows:
aligned reads were counted using htseq-count v.0.6.1p1
(25) and normalized according to the DESeq size factors
method (26). We used fold change ≥2 and FDR <0.05 as
the determination of differentially expressed genes (DEG).
Statistical analysis and plots were performed inside R
environment version 3.1.0. Fastq files have been deposited
to the NCBI repository under the accession number PR-
JNA521683.
Motif enrichment analysis
To identify the RNA-binding proteins (RBPs) around
skipped exons, we extended the rMAPS software (27).
This tool identifies the binding positions of RBPs around
skipped exons. The purpose of rMAPS is to identify known
RBP motifs that are significantly enriched in differentially
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to control (background) events. rMAPS analyzes each set
of 300 nt length sequences, with a sliding window of 50 nt,
and counts the number of times the motif matches each
sequence. The resulting ‘enrichment score’ is then used to
compare local enrichment in the window between signif-
icant exons and background exons by the Wilcoxon rank
sum test. This process results in a set of 250 highly corre-
lated P-values, which rMAPS summarizes by the minimum
(raw) P-value.
We extended rMAPS by proposing a method to iden-
tify intervals significantly enriched for a given RBP. Here,
‘significantly’ means that with high probability, the pro-
portion of false positives (or False Discovery Proportion:
FDP) among any of the selected intervals does not exceed
a user-defined threshold. This method is based on the con-
cept of post-hoc inference, as introduced by Goeman and
Solari (28) and further studied by Blanchard, Neuvial and
Roquain (29). Importantly, the user may choose the thresh-
old on the FDP post hoc, i.e. after data analysis. Compared
with rMAPS, this approach reduces the number of identi-
fied false positives and allows the identification of their pre-
cise binding site. We chose to call significant all the inter-
vals with a post-hoc false discovery proportion (ph-FDP)
<25%. This value represents the maximum frequency of
false positives present in each set of P-values called signifi-
cant.
ChIP-Seq analysis
To study the binding of ERG and FLI1 to DNA in HUVEC
cells, we used ChIP-Seq data available on GEO: GSE109696
for ERG, FLI1 and H3K4me3 binding (30) and GSE124891
for the control. Reads were aligned to the human reference
genome (GRCh37/hg19) with bowtie2 2.2.9 (31). Unin-
formative reads (multimapped reads, duplicated reads and
reads with low mapping score) were filtered out with sam-
tools 1.3 (32). Peaks were called with MACS2 2.1.1 (33)
with the narrow option and input DNA as control. Bedtools
v2.21.0 (34) was used to compare peaks at transcription
start sites (TSS) of ERG- or FLI1-dependent alternatively
spliced genes or 250bp around ERG- or FLI1-regulated
ASEs. For TSS, we considered all ERG and FLI1 peaks
overlapping with TSS. For exons, we removed ERG and
FLI1 peaks overlapping with H3K4me3 peaks and evalu-
ated the presence of peaks within a window spanning from
250 bp upstream to 250 pb downstream of the alternative
exon.
Patient data
RNA-sequencing datasets from Ewing sarcoma patients
were previously published (35) and are available at EGA
under the accession number EGAS00001003333. Clinical
data are available at the ICGC data portal (project refer-
ence: BOCA-FR).
RESULTS
A role for ERG in the control of pre-mRNA splicing
Our recent observation that ERG TFs control gene expres-
sion through regulation of mRNA stability prompted us
to investigate whether they might also be involved in other
co- or post-transcriptional steps of mRNA processing, in-
cluding splicing (3). Toward this aim, we down-regulated
ERG expression in HeLa cells and analyzed transcriptomic
changes by RNA-seq. We chose HeLa cells because they
predominantly express ERG and very little of FLI1 and
FEV, the other two ERG family members (Supplementary
Figure S1A). Transfection with siRNA led to a reduction
of ERG protein levels to <10% of its normal levels (Sup-
plementary Figure S1B). Differential analysis of mRNA
expression levels between control and ERG-depleted cells
identified 2106 genes whose expression level was signifi-
cantly altered by at least 2-fold following ERG knockdown,
including 945 (45%) up- and 1160 (55%) down-regulated
(Supplementary Table S1). Changes in gene expression were
confirmed by RT-qPCR on selected genes, thus validat-
ing our differential expression analysis pipeline (Figure
1A). Differentially expressed genes (DEG) showed signif-
icant enrichment for Gene Ontology (GO) biological pro-
cess terms associated with interferon-gamma response and
regulation of cell migration (Figure 1B). Splicing analysis
revealed that ERG is significantly associated with a large
number of alternative splicing alterations (Figure 1C). By
far, the most frequent splicing event (77.5%, 410/529) was
regulation of alternatively spliced exons (ASEs, also called
cassette exons). These 410 ASEs were consistent across
three biological replicates and included 228 spliced-in (i.e.
alternative exons preferentially skipped after ERG knock-
down) and 182 spliced-out (i.e. alternative exons preferen-
tially included after ERG knockdown) exons in control cells
as compared to ERG-depleted cells (Figure 1D; Supple-
mentary Table S2). GO analysis revealed that differentially
spliced genes (DSG) were significantly associated with var-
ious biological processes related to mRNA metabolism and
cell cycle progression (Figure 1E). Interestingly, we found
no significant overlap between differentially spliced and dif-
ferentially expressed genes, indicating that ERG controls in-
dependent sets of genes at the transcription and splicing lev-
els (Figure 1F).
These observations raised the intriguing possibility that
ERG might have a direct role in splicing regulation, in-
dependent of its transcriptional effects. If ERG can act
as a direct splicing regulator, we expected it to be found
in association with nascent RNA, as splicing mostly oc-
curs co-transcriptionally (36). To test this, we prepared
a fraction corresponding to chromatin and other high
molecular weight nuclear components (HMW) from nu-
clei of HeLa cells. We then extracted RNA- and DNA-
associated proteins from the insoluble Chromatin/HMW
fraction by treating the pellet sequentially with RNase A
and benzonase, according to a previously described proto-
col (37) (Figure 2A). ERG was efficiently extracted from the
Chromatin/HMW fraction by RNase A treatment, indicat-
ing that a portion of ERG associates with chromatin in a
RNA-dependent manner (Figure 2B). Inhibiting transcrip-
tion using actinomycin D reduced the presence of ERG in
the RNA-associated fraction, suggesting that association of
ERG with chromatin is mediated by nascent RNA (Supple-
mentary Figure S2A). As expected, ERG was also found in
the DNA-associated chromatin fraction, as it was solubi-
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Figure 1. ERG controls the HeLa transcriptome at the levels of gene expression and alternative splicing. (A) Correlation between mRNA levels quantified
by RNA-sequencing or qRT-PCR on a set of 22 target mRNAs expected to be up- (FDR<0.05, Log2(FC)>1, red dots) or down- (FDR < 0.05, log2(FC) <
1, green dots) regulated after ERG knockdown in HeLa cells. Results shown are means ± SD (n = 3 independent experiments). (B) Distribution of enriched
GO biological process terms in differentially expressed genes (DEG) following ERG knockdown in HeLa cells. (C) Numbers of significantly differentially
spliced events identified by rMATS after ERG knockdown in HeLa cells with the following criteria: supported by at least 15 unique reads, |PSI| > 10%
and FDR < 0.05. ASE: Alternatively spliced exons, RI: Retained intron, MXE: Mutually exclusive exons, A5SS: Alternative 5′ splice site, A3SS: Alternative
3′ splice site. (D) Heatmap of Z-scores of percent of spliced-in (PSI) values from significantly differentially spliced exons between HeLa cells transfected
either with siCTRL or siERG. (E) Distribution of enriched GO biological process terms associated with differentially spliced genes (DSG, i.e. genes with
at least one ERG-regulated ASE) following ERG knockdown in Hela cells. (F) Overlap between differentially expressed genes and differentially spliced
genes (DSG) in HeLa cells after ERG knockdown. Expected overlap = 39. n.s.: not significant.
insensitive pellet (Figure 2B). Consistent with these find-
ings, FLI1, another member of the ERG family, was also
present in both the RNA- and DNA-associated fractions
of HL-60 cells expressing FLI1 endogenously (Figure 2C).
Curation of two protein-protein interaction databases
(38,39) (BioGRID, https://thebiogrid.org and STRING,
https://string-db.org) identified 97 unique interactors for
ERG (Supplementary Table S3). Enrichment analysis for
GO biological processes terms revealed that a significant
proportion of ERG binding partners (27%; 26 out of 97;
FDR = 7.77E–22) were categorized as ‘mRNA splicing, via
spliceosome’ (GO:0000398) (Supplementary Figure S2B).
These proteins include core components of small nuclear
ribonucleoprotein (snRNP) particles as well as snRNP-
associated factors, spliceosome-associated hnRNPs and
pre-mRNA processing factors. By immunoblot analysis of
ERG immunoprecipitates, we confirmed the association of
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Figure 2. ERG associates with core components of the splicing machinery to control mRNA splicing. (A) Preparation of the nuclear HMW, RNA- and
DNA-associated fractions from HeLa cells. (B) Immunoblot analysis of ERG in total, RNA- and DNA-associated HMW fractions from HeLa cells.
U2AF65, GAPDH and Histone H3 specific antibodies were used as control for fraction purity. (C) Immunoblot analysis of FLI1 in total, RNA- and
DNA-associated HMW fractions from HL-60 cells. U2AF65, GAPDH and Histone H3 specific antibodies were used as control for fraction purity. (D)
Western blot analysis of endogenous ERG immunoprecipitates from RNAse A-treated or untreated lysates from HeLa cells, using antibodies against the
indicated spliceosome components (SF3B2, SF3B3, SF3A1, U170-K, U1C, U2AF65). An anti-ERG antibody was used to control the immunoprecipitation
efficiency. Quantification of the protein levels was performed by signal densitometry relatively to the -ERG immunoprecipitation from untreated lysate.
(E) Diagrams of the SMN2 minigene reporter and MS2-fused ERG constructs. An MS2 binding site is inserted in the intron downstream from exon 7. The
primers for RT–PCR are indicated by arrows. (F) RT-PCR analysis of SMN2 minigene exon 7 inclusion. Samples are RNA from HeLa cells transfected
with the SMN2-MS2 minigene reporter and either FLAG- or FLAG-MS2-CP-tagged versions of FLI1, ERG and FEV. Results shown are means ±
s.e.m (n = 3 independent experiments) relative to FLAG-MS2-CP alone. *P < 0.05; **P < 0.01; ***P < 0.001; n.s.: non-significant by two-tailed unpaired
Student’s t-test. (G) Representation of ERG-deletion constructs. Numbers indicate positions of amino-acids. (H) RT-PCR analysis of SMN2 minigene exon
7 inclusion. Samples are RNA from HeLa cells transfected with the SMN2-MS2 minigene reporter and FLAG-MS2-CP-tagged version of the indicated
ERG deletion variants. Results shown are means ± s.e.m. (n = 3 independent experiments) relative to ERG full-length protein (ERG-FL). *P<0.05; n.s:
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some. These included two U1 snRNP proteins, U1–70K
and U1C; U2AF65, the larger subunit of U2 Small Nu-
clear RNA Auxiliary Factor; and U2 snRNP-associated
proteins SF3B2, SF3B3 and SF3A1 (Figure 2D). Most
of these interactions were maintained when lysates were
treated with RNase A. In contrast, a significant reduction of
the amounts of U1C and U2AF65 co-immunoprecipitating
with ERG was observed, indicating that the association of
ERG with these factors is mediated by RNA. Altogether,
these data indicate that a fraction of ERG is engaged in a
complex network of interactions with spliceosomal proteins
and is present on chromatin-bound nascent RNA, consis-
tent with a possible direct role in pre-mRNA splicing.
To formally test this possibility, we used a splicing re-
porter assay in which an MS2-binding site was inserted
downstream of exon 7 in a minigene that contains exons
6 to 8 of the SMN2 gene (21). FLAG-tagged ERG mem-
bers were expressed with an N-terminal tag derived from the
MS2 bacteriophage coat protein (CP) to enable their direct
tethering to the minigene transcript (Figure 2E). Compared
to MS2-CP alone, tethering of ERG, FLI1 or FEV onto the
intronic MS2 site significantly increased inclusion of exon 7
(Figure 2F, black bars). Importantly, compared to FLAG
alone, ERG family proteins had no effect when not fused
to MS2-CP (Figure 2F, white bars), indicating that their
ability to control exon inclusion of the reporter minigene
strictly relies on their recruitment to the target pre-mRNA.
To identify the domain of ERG responsible for this effect,
we generated a series of MS2-ERG fusion constructs lack-
ing the PNT (pointed), ATAD (amino-terminal activation
domain), ETS (DNA-binding) or CTAD (carboxy-terminal
activation domain) domains, and tested their effects on the
SMN2 reporter (Figure 2G). Among these constructs, the
variant lacking the CTAD (ERG-CTAD) was the only
one showing a significantly reduced effect on exon inclusion
(Figure 2H). These results indicate that the CTAD, which is
shared among the ERG subfamily members but not other
ETS family members (Supplementary Figure S2C), is im-
portant for their ability to promote exon inclusion. Because
the variant lacking the ETS domain is unable to bind DNA
(40) but still promotes inclusion of the reporter exon, these
results are consistent with the idea that the function of ERG
in pre-mRNA splicing is direct, requiring its recruitment to
pre-mRNA and independent of its transcriptional activity.
ERG and RBFOX2 control a common splicing program in
HeLa cells
To investigate the mechanisms by which ERG regulates
splicing, we performed motif enrichment analysis on our
dataset of ERG-regulated ASEs in HeLa cells, using a com-
pilation of 110 known RNA-binding protein (RBP) binding
sites from the literature (41,42). Enrichment was scored rel-
ative to non-regulated exons. Motifs for RBPMS and for
the RBFOX family stood out from this analysis as the first
and second most significantly enriched motifs, respectively
(Figure 3A). Interestingly, both RBPs are important splic-
ing regulators for various developmental processes (43,44).
We decided to focus our efforts on RBFOX factors, which
have been extensively characterized as master splicing reg-
ulators. Enrichment of the RBFOX motif was the highest
in proximal intronic sequences upstream of ERG-spliced-
out ASEs, adding to the hypothesis that ERG controls alter-
native splicing through an RBFOX-dependent mechanism
(Figure 3B).
To explore this possibility, we examined the effects of
knocking-down RBFOX2 on the mRNA splicing programs
of HeLa cells. Among the RBFOX family, which include
RBFOX1, RBFOX2 and the neuron-specific RBFOX3,
RBFOX2 is the only member expressed in HeLa cells (Sup-
plementary Figure S3A). Transfection with a RBFOX2
siRNA resulted in efficient reduction of RBFOX2 mRNA
levels so as to reduce RBFOX2 protein levels to approxi-
mately 30% of normal, without inducing expression of RB-
FOX1 or RBFOX3 (Supplementary Figures S3B and S3C).
In agreement with previous studies (45,46), knockdown of
RBFOX2 mostly resulted in ASEs (55.5%, 399/719, Fig-
ure 3C). Out of 399 regulated ASEs, 233 were spliced-in
and 166 were spliced-out in control cells as compared to
RBFOX2-depleted cells (Supplementary Table S4). Com-
parison with our dataset of ERG-regulated ASEs revealed
that a highly significant proportion (132/410; 32.2%, P <
10E–50) of ERG-regulated ASEs were also sensitive to RB-
FOX2 knockdown (Figure 3D). Strikingly, 96% of the ASEs
regulated by both RBFOX2 and ERG were similarly reg-
ulated following knockdown of either of the two proteins
(Figure 3E). Examples of independent or co-regulation by
RBFOX2 and/or ERG were validated by RT-PCR analy-
sis for a series of ASEs (Supplementary Figure S3D). Alto-
gether, these data identify a large set of ASEs that are simi-
larly regulated by both ERG and RBFOX2 in HeLa cells.
ERG and FLI1 control a RBFOX2-dependent splicing pro-
gram in HUVECs
To extend our findings, we repeated these analyses in hu-
man primary umbilical vein endothelial cells (HUVECs).
HUVECs express both ERG and FLI1, which have been
recognized as master regulators of endothelial gene expres-
sion programs (30). This cellular model thus offers the op-
portunity to compare ERG- and FLI1-mediated splicing ef-
fects in a biologically relevant context. We knocked down
ERG and FLI1 using specific siRNAs (Supplementary Fig-
ure S4A) and first analyzed gene expression changes. As ex-
cepted, knocking down ERG or FLI1 dramatically altered
gene expression levels in HUVECs as we identified respec-
tively 4212 (1607 up and 2605 down) and 3092 (1491 up and
1601 down) genes whose expression was significantly mod-
ified across three replicates (Supplementary Figure S4B,
Supplementary Tables S5 and S6). As previously reported,
ERG and FLI1 significantly co-regulated a large number of
genes (Supplementary Figure S4C, D). Functional enrich-
ment analysis revealed that ERG- and FLI1-regulated genes
were mainly associated with GO terms related to cell cycle
progression and chromosome segregation (Supplementary
Figure S4E). All these results are fully consistent with pre-
vious reports and confirm the predominant roles of ERG
and FLI1 in controlling the endothelial transcriptome (30).
To confirm a role for ERG factors in alternative splic-
ing regulation, we also profiled splicing changes in ERG- or
FLI1-knocked down HUVEC cells. As observed in HeLa
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Figure 3. ERG regulates an RBFOX2-dependent splicing program. (A) Post-hoc false discovery proportion (ph-FDP) values of motif enrichment analysis
performed on ERG-regulated spliced-out exons in HeLa cells. Red line represents the upper-bound of the significant RBPs at 25% FDP. (B) RBFOX motif
enrichment analysis upstream and downstream of ERG-regulated exons in HeLa cells. Red and blue lines represent intronic RBFOX motif scores around
ERG spliced-in or spliced-out exons, respectively. Unaffected exons are generated from exons not modulated following ERG knockdown (FDR > 0.5,
maxPSI > 0.15 and minPSI < 0.85). (C) Numbers of significantly differentially spliced events identified after RBFOX2 knockdown in HeLa cells. ASEs:
Alternatively spliced exons, RI: Retained intron, MXE: Mutually exclusive exons, A5SS: Alternative 5′ splice site, A3SS: Alternative 3′ splice site. (D)
Overlap of significantly differentially spliced exons modulated upon ERG or RBFOX2 knockdown in HeLa cells. Expected overlap = 10. (E) Proportion
of common target exons upon ERG and RBFOX2 inhibition shown in (D) (n = 132) categorized as ‘similar’ (blue sector) or ‘opposite’ (orange sector)
depending on whether delta PSI values vary in respectively the same or opposite direction.
in siERG-treated HUVEC cells were ASEs, with more than
865 ASEs being spliced-in (n = 667) or spliced-out (n
= 198) in control versus ERG-depleted condition (Figure
4A, Supplementary Table S7). Similar observations were
also made in FLI1-depleted HUVECs, where we detected
906 ASEs, 628 being more included and 278 more ex-
cluded in control cells (Figure 4A, Supplementary Table
S8). GO analysis of DSGs revealed that ERG- and FLI1-
dependent ASEs were found in genes associated with bi-
ological processes related to cell and plasma membrane
morphogenesis, and adherens junction organization (Fig-
ure 4B). ERG and FLI1 co-regulated a significant num-
ber of ASEs (338 ASEs, Figure 4C). The effects of ERG
or FLI1 on these common ASEs were almost systemat-
ically similar (i.e. they affected exon inclusion/exclusion
in the same direction in 97.9% cases) (Figure 4D). Alto-
gether, these observations confirm that ERG and FLI1 are
key TFs shaping the endothelial transcriptome, but extend
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Figure 4. ERG and FLI1 shape the transcriptome at the level of gene expression and mRNA splicing in HUVECs. (A) Numbers of significantly differen-
tially spliced events identified after ERG or FLI1 knockdown in HUVECs using rMATS with the following criteria: supported by at least 15 unique reads,
|PSI| > 10% and FDR < 0.05. ASE: Alternatively spliced exons, RI: Retained intron, MXE: Mutually exclusive exons, A5SS: Alternative 5′ splice site,
A3SS: Alternative 3′ splice site. (B) Distribution of enriched GO biological process terms associated with differentially spliced genes (DSG, i.e. genes with
at least one ERG-regulated ASE) following ERG (top) or FLI1 (bottom) knockdown in HUVECs. (C) Overlap of significantly differentially spliced exons
modulated upon ERG or FLI1 knockdown in HUVECs. Expected overlap = 14. (D) Proportion of common target exons upon ERG or FLI1 inhibition
shown in (C) (n = 338) categorized as ‘similar’ (blue sector) or ‘opposite’ (orange sector) depending on whether delta PSI values vary in respectively the
same or opposite direction. (E) Overlap of significantly differentially spliced exons modulated upon ERG, FLI1 or RBFOX2 knockdown in HUVECs.
Expected overlap: FLI1/ERG = 14, FLI1/RBFOX2 = 8, ERG/RBFOX2 = 8. (F) Heatmap of Z-scores of percent of spliced-in (PSI) values from common
significantly differentially spliced exons between HUVEC cells transfected either with siERG, siFLI1 or siRBFOX2, relative to siCTRL. (G) Proportion of
common target exons upon ERG and RBFOX2 or FLI1 and RBFOX2 inhibition in HUVECs shown in (E) (n = 193 and n = 203, respectively) categorized
as ‘similar’ (blue sector) or ‘opposite’ (orange sector) depending on whether delta PSI values vary in respectively the same or opposite direction. (H) We
compared genes with no ASEs (control group) and genes with ASEs (ERG-dependent in light blue and FLI1-dependent in dark blue). The barplots rep-
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Our observations in HeLa cells suggested that ERG con-
trols alternative splicing via a RBFOX2-related mecha-
nism and independently of its DNA-binding activity. To
extend these observations to HUVECs, we first compared
RBFOX2-, ERG and FL1-dependent ASE changes. Af-
ter knocking down RBFOX2 in HUVECs and profiling
associated splicing changes, we identified 531 RBFOX2-
dependent ASEs (Supplementary Table S9). Strikingly,
51,4% (273/531) of RBFOX2-dependent ASEs were also
affected by depletion of ERG or FLI1 (Figure 4E). Hier-
archical clustering analysis (Figure 4F) and comparison of
the direction of splicing regulation (i.e. spliced-in or spliced-
out, Figure 4G) of the ASEs common to RBFOX2, ERG
and FLI1 confirmed our observations in HeLa cells for
ERG and RBFOX2, i.e. knocking down ERG or FLI1 re-
capitulated RBFOX2-depletion in most cases (91.9% and
92.4% for ERG and FLI1, respectively). These observations
support a functional collaboration between ERG TFs and
RBFOX2 in regulating pre-mRNA alternative splicing.
To gain further insights into the underlying mechanism,
we tested whether the splicing function of ERG factors
might be related to their transcriptional and DNA-binding
ability. As observed in HeLa cells, we found no signifi-
cant enrichment for ERG-regulated DEG among ERG-
regulated DSG (Supplementary Figure S4F). In addition,
analysis of publicly available ChIP-Seq datasets for ERG
and FLI1 in HUVECs (30) revealed no significant enrich-
ment of ERG or FLI1 peaks around the TSS of differen-
tially spliced genes or 250 bp around ASEs (Figure 4H).
We believe that these observations argue against a model
where ERG or FLI1 predominantly affect pre-mRNA splic-
ing via indirect mechanisms related to their DNA binding.
They rather suggest that ERG factors control a RBFOX2-
dependent splicing program, independently of their pres-
ence on DNA.
ERG associates with RBFOX2 via its CTAD and is part of
the RBFOX2-associated splicing complex LASR
Knocking-down ERG had no impact on RBFOX2 ex-
pression (Supplementary Figure S5A), ruling out the triv-
ial explanation that ERG might indirectly participate in
RBFOX2-dependent splicing regulation by controlling the
expression level of RBFOX2. Next, we tested whether both
proteins may be found in the same complex. In HeLa
cells, we confirmed that endogenous RBFOX2 readily co-
immunoprecipitates with endogenous ERG in a RNase-
insensitive manner (Figure 5A). To extend these obser-
vations to other members of the families, we conducted
co-immunoprecipitation experiments using exogenously ex-
pressed FLAG-tagged ERG family members and HA-
tagged RBFOX1 or Myc-tagged RBFOX2 in HEK293 cells.
Endogenously, these cells express no detectable levels of
ERG family proteins and only very low levels of endoge-
nous RBFOX2. Anti-FLAG immunoprecipitation followed
by western blot analysis revealed that HA-RBFOX1 (Sup-
plementary Figure S5B) and Myc-RBFOX2 (Figure 5B)
co-immunoprecipitate with ERG, FLI1 and FEV FLAG-
tagged constructs. Using FLAG-tagged ERG variants lack-
ing individual domains to identify the RBFOX2-interacting
region of ERG, we found that only the ERG variant lack-
ing the CTAD region, shown above to be important for
the splicing activity of ERG in the SMN2 reporter assay,
had lost the ability to associate with RBFOX2 (Figures 2H
and 5C). Protein interaction assays based on complemen-
tation of the Gaussia luciferase (gPCA) (47) confirmed that
the CTAD is required for association with RBFOX2 and
demonstrated that both proteins are in close proximity in
vivo (Figure 5D). These data demonstrate that ERG family
proteins associate with RBFOX2 through their conserved
CTAD domain (Supplementary Figure S2C).
Recently, the splicing activity of RBFOX proteins was
shown to rely on their association with a large complex
of 8 RBPs (Matrin-3, NF90, hnRNP M, DDX5, hnRNP
F/H, NF45 and hnRNP C) called LASR (Large Assem-
bly of Splicing Regulators) (37). Interestingly, five compo-
nents of LASR (DDX5, hnRNP M, hnRNP F/H, hnRNP
C) are found among the 26 splicing-related ERG partners in
protein-protein interaction databases (Supplementary Ta-
ble S3). In agreement with this, we found that endogenous
ERG co-immunoprecipitates with all LASR components
(Figure 5E). Importantly, the co-immunoprecipitation of
LASR components with ERG was dramatically reduced
in RBFOX2-depleted cells, albeit to different extents, sug-
gesting that RBFOX2 is essential to bridge ERG and
LASR.
We then looked at ERG and RBFOX2 association
with three pre-mRNAs (ENAH, FLNB and MPRIP) that
were similarly regulated by both factors and have an
RBFOX consensus motif in their vicinity. Using RNA-
immunoprecipitation experiments, we confirmed that RB-
FOX2 specifically associates with these pre-mRNAs, but
not with the non-regulated GAPDH pre-mRNA (Fig-
ure 5F). RBFOX2 association with the three target pre-
mRNAs was independent of the presence of ERG. Inter-
estingly, ERG was also associated with these three target
pre-mRNAs, but not with the GAPDH pre-mRNA (Fig-
ure 5G). Because our RNA-immunoprecipitation experi-
ments were done on formaldehyde-crosslinked cells, these
data demonstrate that ERG is in a complex with its target
pre-mRNAs, either due to direct RNA binding or through
an intermediate protein. The association of ERG with its
target pre-mRNAs was not affected by RBFOX2 depletion
(Figure 5G), suggesting that it is not dependent on RB-
FOX2.
Altogether, our data suggest a model, where the simi-
lar effects of ERG and RBFOX2 on the inclusion of spe-
cific exons in pre-mRNAs rely on (i) the association of
both factors with their common target pre-mRNAs, inde-
pendently of each other; and (ii) their association, with
RBFOX2 recruiting ERG to functional RBFOX2/LASR
complexes.
EWS-FLI1 and RBFOX2 are part of the same complex and
converge on a splicing program in Ewing sarcoma cells
While EWS-FLI1 is known to affect a large-scale splicing
program in Ewing sarcoma cells (11), its function in splicing
has been assumed to rely on its EWS moiety (10). Interest-
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Figure 5. ERG physically associates with RBFOX2 through its C-terminal domain. (A) Western blot analysis of endogenous ERG immunoprecipitates from
RNAse A-treated or untreated lysates from HeLa cells, using an RBFOX2 antibody. An anti-ERG antibody was used to control the immunoprecipitation
efficiency. (B) Immunoprecipitation of FLAG-tagged ERG members (FLI1, ERG and FEV) and anti-Myc western blotting. Samples are lysates from
HEK293 cells transfected with Myc-RBFOX2 alone or with either of the FLAG-tagged ERG members. (C) Immunoprecipitation of FLAG-tagged ERG
deletion variants and anti-Myc and anti-FLAG western blotting. Samples are RNAse A-treated lysates from HEK293 cells transfected with Myc-RBFOX2
alone or with either of the FLAG-tagged ERG variants. (D) Protein interaction assay between RBFOX2 and ERG full-length or an ERG variant lacking
the CTAD domain, using the gaussia princeps luciferase complementation method. Results are means ± s.e.m. from one representative experiment out
of 3. (E) Immunoprecipitation of ERG followed by western blotting analysis using antibodies directed against the indicated components of the LASR
complex. Samples are whole-lysates or anti-ERG immunoprecipitates from RNAse A-treated HeLa cell lysates transfected with control (siCTRL) or
specific RBFOX2 siRNA (siRBFOX2). Quantification of the protein levels was performed by signal densitometry relatively to the siCTRL condition.
(F) RNA-immunoprecipitations from HeLa cells transfected with control siRNA (siCTRL) or with siRNA against ERG (siERG) using control Ig (IP
CTRL) or an antibody against RBFOX2 (IP RBFOX2). The presence of mRNA for GAPDH, ENAH, FLNB and MPRIP, all of which are subjected
to ERG-dependent ASE was detected by RT-qPCR. Results are expressed as means±SD from five independent experiments, expressed relative to levels
of the mRNAs in input. n.s.: not significant. (G) RNA-immunoprecipitations from HeLa cells transfected with control siRNA (siCTRL) or with siRNA
against RBFOX2 (siRBFOX2) using control Ig (IP CTRL) or an antibody against ERG (IP ERG). The presence of mRNA for GAPDH, ENAH, FLNB
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moiety might contribute to EWS-FLI1 splicing function.
To test this hypothesis, we first evaluated whether EWS-
FLI1 associates with RBFOX2 in Ewing sarcoma cells. Co-
immunoprecipitation experiments in A673/TR/shEF (20),
a well-characterized Ewing sarcoma cell line, revealed the
presence of EWS-FLI1 in endogenous RBFOX2 complexes
(Figure 6A). This association was resistant to RNase A
treatment and mediated by the FLI1 moiety, as it was ob-
served for both FLI1 and EWS-FLI1, but not for EWS
(Figure 6B). The demonstration of an association between
EWS-FLI1 and RBFOX2 prompted us to further investi-
gate the potential role of RBFOX2 in EWS-FLI1-mediated
splicing regulation.
First, we identified the set of alternative splicing events
regulated by EWS-FLI1 using the A673/TR/shEF cell line
that harbors a doxycycline-inducible shRNA targeting the
EWS-FLI1 fusion transcript (20). RNA-seq was performed
after seven days of doxycycline (DOX) treatment (d7),
which leads to a robust depletion of EWS-FLI1 (Supple-
mentary Figure S6A). Alternative splicing analysis revealed
that knockdown of EWS-FLI1 mostly resulted in ASEs
(72.3%, 1360/1880, Figure 6C and Supplementary Table
S10). Among these ASEs, we validated a set of 20 events
by RT-PCR (Figure 6D). We also performed RNAseq ex-
periments 10 days (d17) and 15 days (d22) after washing
out DOX from the media to re-allow EWS-FLI1 expression
(Supplementary Figure S6B). We observed that most ASEs
were reverted to their basal levels 10 days later (d17), when
EWS-FLI1 expression was fully restored (Supplementary
Figure S6C). This experiment shows that detected ASEs are
fully reversible and strongly correlate with EWS-FLI1 ex-
pression level.
Among EWS-FLI1-dependent ASEs, we then looked for
potential RBP motifs upstream or downstream of regu-
lated exons. As previously observed for ERG-dependent ex-
ons in HeLa cells, we found a significant enrichment of the
RBFOX-binding motif around EWS-FLI1-regulated exons
(Figure 6E). To further support a functional link between
EWS-FLI1 and RBFOX2, we analyzed splicing changes
following RBFOX2 depletion in A673/TR/shEF Ewing
sarcoma cells (Supplementary Figure S6D). Knockdown of
RBFOX2 was associated with 768 splicing events. As ob-
served in HeLa and HUVEC cells, ASEs accounted for the
majority of splicing events regulated in Ewing sarcoma cells
following RBFOX2 knockdown (74,1%, 569/768) (Supple-
mentary Figure S6E, Supplementary Table S11). Consis-
tent with the enrichment of the RBFOX-binding motif
around EWS-FLI1-regulated exons, comparison of EWS-
FLI1- and RBFOX2-regulated ASEs revealed a highly sig-
nificant subset of common targets, as EWS-FLI1 regu-
lated more than one third (36.7% 209/569) of RBFOX2-
dependent ASEs (Figure 6F). However, in striking contrast
with what we observed for wild-type FLI1 (and ERG), de-
pletion of EWS-FLI1 or RBFOX2 did not systematically
have similar effects on common ASEs. Instead, knocking
down EWS-FLI1 had an opposite effect to that of knock-
ing down RBFOX2 in 50.2%, (105/209) of cases (Figure
6G). Altogether, these data indicate that EWS-FLI1 and
RBFOX2 interact with each other, and regulate a common
set of ASEs in Ewing sarcoma cells, either in a similar or
opposite manner.
ADD3 splicing induced by EWS-FLI1 is a phenotypic-driver
in Ewing sarcoma
RBFOX2 is a key regulator of mesenchymal-specific splic-
ing programs that promote the mesenchymal phenotype
(48,49). In contrast, EWS-FLI1 is considered as a repres-
sor of mesenchymal features in Ewing sarcoma cells (50–
52). Based on our observation that EWS-FLI1 represses
a large subset of RBFOX2-regulated ASEs, we thus hy-
pothesized that EWS-FLI1 might inhibit specific RBFOX2-
dependent ASEs to antagonize mesenchymal features in
Ewing sarcoma cells. Alternative splicing events associ-
ated with EMT have been recently explored by induction
of the EMT promoting factor ZEB1 in lung carcinoma
H358 cells (53). Despite the different cellular backgrounds,
we found a highly significant overlap between EWS-FLI1-
regulated ASEs, RBFOX2-regulated ASEs, and ASEs asso-
ciated with EMT (Figure 7A). Hierarchical clustering illus-
trated similarities between the splicing landscapes of EWS-
FLI1-knocked-down A673/TR/shEF cells and of ZEB1-
expressing H358 cells, while normal H358 clustered with
control A673/TR/shEF cells (Figure 7B), consistent with
the idea that EWS-FLI1 is a repressor of mesenchymal fea-
tures. This indicates that decreasing expression of EWS-
FLI1 in Ewing sarcoma cells induces a mesenchymal splic-
ing program, in addition to a mesenchymal gene expression
program as previously reported (50–52). Accordingly, func-
tional analysis revealed that common ASEs of EWS-FLI1
and RBFOX2 (n = 209, Supplementary Table S12) are en-
riched in genes linked to cytoskeleton and membrane orga-
nization (Figure 7C).
We were particularly interested in genes containing ASEs
that were antagonistically regulated by EWS-FLI1 and RB-
FOX2, and turned our attention towards the ADD3 gene,
which encodes an EMT-associated protein playing a role in
actin cytoskeleton remodeling (18). By RT-PCR, we veri-
fied that EWS-FLI1 promotes the ADD3-L isoform, which
contains exon 14, whereas RBFOX2 reduces the inclusion
of exon 14 of ADD3 in Ewing sarcoma cells (Figure 7D). We
further validated the regulation of ADD3 exon 14 splicing
by EWS-FLI1 depletion using siRNA transfection in a sec-
ond Ewing sarcoma cell line (MHH-ES1, Supplementary
Figure S7A). RNA-seq analysis of a collection of 43 Ewing
tumors showed that the relative inclusion levels of ADD3
exon 14 were positively correlated with EWS-FLI1 expres-
sion levels (P = 0.017; R = 0.39) (Supplementary Figure
S7B).
To further understand how EWS-FLI1 might antago-
nize RBFOX2-dependent splicing of ADD3, we first ex-
amined RBFOX2 expression in EWS-FLI1-expressing ver-
sus -knocked down A673/TR/shEF cells. We found that
RBFOX2 mRNA expression levels did not change follow-
ing DOX-mediated downregulation of EWS-FLI1 (Sup-
plementary Figure S7C), thus excluding the trivial expla-
nation that EWS-FLI1 might repress RBFOX2 expres-
sion. Next, because a potential RBFOX2-binding mo-
tif is found near ADD3 exon 14, we performed RNA-
immunoprecipitation experiments of endogenous RBFOX2
in the A673/TR/shEF cell line upon DOX treatment.
Quantitative RT-PCR analysis revealed that the associa-
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Figure 6. EWS-FLI1 fusion protein associates with RBFOX2 and controls a common splicing program. (A) Immunoprecipitation of endogenous RBFOX2
followed by anti-EWS-FLI1 and anti-RBFOX2 western blotting. Samples are control (IgG) and anti-RBFOX2 immunoprecipitates from A673/TR/shEF
cells. An anti-RBFOX2 antibody was used to control the immunoprecipitation efficiency. (B) Immunoprecipitation of FLAG-tagged EWS, FLI1 or EWS-
FLI1 and anti-Flag and anti-Myc western blotting. Samples are RNAse A-treated lysates from HEK293 cells transfected with Myc-RBFOX2 together
with the FLAG empty vector or with FLAG-tagged EWS, FLI1 or EWS-FLI1. (C) Numbers of significantly differentially spliced events identified by
rMATS after EWS-FLI1 inhibition in A673/TR/shEF cells. ASE: Alternatively spliced exons, RI: Retained intron, MXE: Mutually exclusive exons,
A5SS: Alternative 5′ splice site, A3SS: Alternative 3′ splice site. (D) Correlation of PSI values analyzed by RT-PCR or RNA-seq from a subset of exons
showing differential splicing between A673/TR/shEF cells at day0 and day7 of doxycycline treatment. (E) Post-hoc false discovery proportion (ph-FDP)
values of motif enrichment analysis performed on EWS-FLI1-regulated spliced-in exons in A673/TR/shEF cells. Red line represents the upper-bound of
the significant RBPs at 25% FDP. (F) Overlap between EWS-FLI1- and RBFOX2-dependent exons in A673/TR/shEF cells. Expected overlap = 22. (G)
Proportion of common target exons upon EWS-FLI1 and RBFOX2 inhibition shown in (F) (n = 209) categorized as ‘similar’ (blue sector) or ‘opposite’
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Figure 7. ADD3 pre-mRNA splicing induced by EWS-FLI1 participates in Ewing sarcoma phenotype. (A) Overlap between EWS-FLI1- or RBFOX2-
dependent exons in A673/TR/shEF cells and EMT-associated splicing events in H358 human epithelial cells. All pair-wise comparisons are highly sig-
nificant (P-value < 10–50). (B) Heatmap of Z-scores of percent of spliced-in (PSI) values from significantly differentially spliced exons in EWS-FLI1high
(A673/TR/shEF cells without Dox treatment) versus EWS-FLI1low (A673/TR/shEF cells at day 7 of Dox treatment) and in epithelial versus mesenchymal-
like ZEB1-expressing H358 cells. (C) Distribution of top significant GO biological process terms from genes containing EWS-FLI1 and RBFOX2-regulated
exons. Number of spliced genes regulated by EWS-FLI1 and RBFOX2 in each GO are indicated in brackets. (D) RT- PCR analysis of ADD3 exon 14 splic-
ing. Samples are RNA from A673/TR/shEF cells expressing (-DOX) or not (+DOX) EWS-FLI1 (left) and RNA from A673/TR/shEF cells expressing
EWS-FLI1 and transfected with control siRNA (siCTRL) or a specific RBFOX2 siRNA (siRBFOX2). (E) RNA-immunoprecipitation experiments using
anti-RBFOX2 antibodies followed by RT-qPCR to detect ADD3 transcripts. Samples are RNA from A673/TR/shEF cells expressing (–DOX) or not
(+DOX) EWS-FLI1. Results shown are means ± s.e.m. (n = 3 independent experiments) relative to the –DOX condition. *P < 0.05 by two-tailed un-
paired Student’s t-test. (F) Immunofluorescence of actin filaments stained with phalloidin (green channel) and DAPI (blue channel) of A673/TR/shEF
cells and cells deleted for ADD3 exon 14 genomic region (A673/TR/shEF Δexon14 ADD3). (G) Measurement of cell area of A673/TR/shEF cells and
cells deleted for ADD3 exon 14 genomic region (A673/TR/shEF Δexon14 ADD3). Data are represented as mean ± s.e.m. (n > 100 cells). ****P < 0.0001.
(H) Three-dimensional type-I collagen multicellular spheroid invasion assay of A673/TR/shEF cells and cells deleted for ADD3 exon 14 genomic region
(A673/TR/shEF Δexon14 ADD3). Red dotted lines represent the initial spheroid area. (I) Immunofluorescence of actin filaments stained with phalloidin
(green channel) and DAPI (blue channel) of A673/TR/shEF cells treated with DOX for 7 days (EWS-FLI1low expressing cells) and transfected with either
empty vector or vector expressing the ADD3-L isoform. (J) Kaplan-Meier curve of ADD3 exon 14 PSI values in 43 Ewing tumors showing significant
differences between tumors expressing high and low levels of ADD3-L isoform. Tumors were separated by k-means clustering. Number of tumors in each
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was strongly decreased in the presence of EWS-FLI1
(Figure 7E). These data suggest that EWS-FLI1 pro-
motes ADD3 exon 14 inclusion and ADD3-L isoform
production by preventing RBFOX2 binding to ADD3
pre-mRNA.
Depletion of EWS-FLI1 induces a switch towards a mes-
enchymal phenotype, with cells displaying increased actin
stress fibers, cell size, and invasion capacity (50). Interest-
ingly, preventing the expression of the ADD3-L isoform in
EWS-FLI1 expressing cells, either by using a specific siRNA
targeting exon 14 in A673/TR/shEF and MHH-ES1 cell
lines (Supplementary Figure S7D) or by removing this
exon using a CRISPR/Cas9 approach in A673/TR/shEF
cells (Supplementary Figure S7E–G), led to increased actin
stress fibers (Figure 7F and Supplementary Figure S7H).
Further analysis of cells with CRISPR deletion of ADD3
exon 14 showed an increase in cell size and invasion ca-
pacity (Figure 7G and H). Conversely, in DOX-treated
A673/TR/shEF cells, which express low levels of EWS-
FLI1 and therefore of ADD3-L (See Figure 7D), ectopic ex-
pression of the ADD3-L isoform reduced stress fibers for-
mation (Figure 7I and Supplementary Figure S7I). These
observations strongly suggest that the ADD3-L isoform
contributes to the repression of mesenchymal features by
EWS-FLI1 in Ewing sarcoma cells.
Finally, we investigated the prognostic significance of
ADD3-L mRNA expression in patients with Ewing sar-
coma. We generated Kaplan-Meier curves by stratifying pa-
tients into 3 groups using k-means clustering: tumors with
high, intermediate and low inclusion of ADD3 exon 14. Pa-
tients with high inclusion levels of ADD3 exon 14 showed a
significantly better survival than patients with low inclusion
levels (Figure 7J). This observation supports the hypothesis
that high levels of the ADD3-L isoform in tumors repress
the mesenchymal phenotype of Ewing sarcoma cells hence
decreasing their metastatic potential. Altogether, these data
strongly suggest that the regulation of ADD3 splicing by
EWS-FLI1 is important for Ewing sarcoma biology.
DISCUSSION
TFs are traditionally defined as sequence-specific DNA-
binding proteins controlling transcription initiation. Al-
though mounting evidence indicates that they can also par-
ticipate in downstream mRNA processing events, in par-
ticular splicing, the prevailing model suggests that they do
so via indirect mechanisms (15). These include (i) modifi-
cation of RNA polymerase II elongation rate, which mod-
ulates splicing by altering the kinetics of exposure of splice
sites; (ii) recruitment of transcriptional coactivators that af-
fect splicing and (iii) modulation of the expression of direct
splicing regulators (16). More recently, it was shown that
some TFs can bind directly to pre-mRNA and control al-
ternative splicing via unknown but direct mechanisms (17).
Here, we report that the transcription factor ERG controls
hundreds of alternative splicing events. Although some of
these events might be indirectly regulated by ERG (i.e. if
ERG controls the expression levels of splicing regulators),
our data strongly argue in favor of a direct role for ERG in
pre-mRNA splicing. First, ERG TFs are found in associa-
tion with nascent pre-mRNA. Second, a splicing minigene
assay shows that ERG TFs specifically affect inclusion rates
of the cassette exon only when tethered to the reporter tran-
script. Third, ERG co-immunoprecipitates with the splicing
regulator RBFOX2 and its key functional partners within
the LASR splicing complex, which is required for the splic-
ing activity of RBFOX2 (37). Fourth, knockdown exper-
iments demonstrate that ERG TFs and RBFOX2 control
a common set of ASEs with an enrichment in RBFOX2
binding motifs in the preceding intron; it is thus likely that
ERG-dependent splicing relies on the recognition of these
motifs by RBFOX2. Fifth, in addition to LASR, ERG en-
gages in a variety of interactions with core spliceosome con-
stituents, such as SF3A1, U1C, U1–70K and U2AF65 (see
Figure 2D). Strikingly, RBFOX1/2 have also been shown to
either interact or interfere with these proteins (54,55). Sixth,
our findings suggest that the splicing function of ERG is
independent of its DNA-binding and transcriptional activ-
ity. Indeed, there was no significant overlap between differ-
entially expressed and differentially spliced genes in ERG
knockdown cells; there was no enrichment of ERG bind-
ing sites in DNA regions around ERG regulated exons and
the TSS of corresponding genes; and a transcriptionally in-
active ERG variant lacking the DNA-binding domain (40)
exhibited full splicing activity in our minigene assay. Finally,
further analyses on exons co-regulated by both ERG and
RBFOX2 indicate that both factors associate (directly or
indirectly) with pre-mRNAs around these exons, indepen-
dently of each other.
While the enrichment of RBFOX2-binding sites around
ERG-regulated exons raised the possibility that RBFOX2
might recruit ERG onto pre-mRNA, this model is ruled
out by the fact that ERG association with its target pre-
mRNAs is independent of RBFOX2. Conversely, a model
where DNA-bound ERG might recruit RBFOX2 to ERG
target genes and promote its binding to its RNA recogni-
tion motifs around alternative exons, is ruled out by the
lack of enrichment of ERG binding sites in DNA regions
around ERG regulated exons and the TSS of correspond-
ing genes, and by the fact that ERG depletion does not af-
fect RBFOX2 association with target pre-mRNAs. Impor-
tantly, ERG incorporation into the RBFOX2/LASR com-
plex is largely dependent on RBFOX2. Altogether, our data
suggest a model, where pre-mRNA-bound RBFOX2 is not
responsible for bridging ERG onto its target pre-mRNAs,
but to the LASR complex. Because we found that ERG also
associates with several components of the spliceosome, its
presence within LASR might affect the activity and/or the
composition of the splicing complex around regulated ex-
ons or alter the interaction of the RBFOX2/LASR com-
plex with the splicing machinery. The network of inter-
actions between ERG, RBFOX2/LASR, spliceosome core
components and potential additional RBPs, and the dy-
namic regulation of these interactions are very exciting is-
sues that deserve to be further investigated. Beyond ERG,
our observations provide support to the idea that alterna-
tive splicing regulation is a complex process governed by a
dynamic protein network including spliceosomal proteins
and RBPs but also TFs (17,56). Our work also adds to
a growing body of evidence showing that TFs are multi-
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The overlap between ERG- and RBFOX2-regulated
ASEs is not total, suggesting that both proteins can also
regulate alternative splicing independently of each other.
Along these lines, we found that ERG members, through
their CTAD, co-immunoprecipitate with RBPMS (RNA-
binding protein with multiple splicing) and QKI (Quak-
ing Homolog, KH Domain RNA Binding) ((3) and unpub-
lished observations), two splicing regulators whose binding
motifs were significantly enriched around ERG- or EWS-
FLI1-dependent exons, respectively. Like RBFOX2, QKI
and RBPMS regulate alternative splicing during cell differ-
entiation (58–60), and QKI promotes mesenchymal splic-
ing patterns (53). On these grounds, it would be interesting
to test the possibility of a functional cooperation between
ERG TFs and other RBPs, including RBPMS and QKI.
Perturbation of alternative splicing programs is a feature
of Ewing sarcoma, and has been attributed to the pres-
ence of oncogenic fusion proteins (e.g. EWS-FLI1) (10–
12) However, while EWS-FLI1 function in splicing was
thought to be due to its EWS moiety, our findings demon-
strate that the FLI1-derived moiety is also a major con-
tributor. In sharp contrast to the convergent effects shared
by RBFOX2 and wild-type ERG family proteins on their
common set of ASEs, the EWS-FLI1 fusion antagonizes
a large proportion of RBFOX2-dependent ASEs. The ob-
servation that RBFOX2 binding to its target pre-mRNA,
ADD3 is increased after depletion of EWS-FLI1 in Ew-
ing sarcoma cells, suggests that EWS-FLI1 expression may
interfere with RNA binding by RBFOX2. Splicing regula-
tion often requires condensation of cooperative splicing fac-
tors into phase-separated complexes via aggregation of low-
complexity (LC) or intrinsically discorded (ID) domains
commonly found in RBPs (61). The C-terminal domain of
RBFOX2, contains a LC/ID region that mediates higher-
order assembly of RBFOX/LASR complexes and is re-
quired for its splicing activity (37,62). Interestingly, EWS-
FLI1 also contains a LC region derived from EWS and
can participate in phase transition processes (7,63). Thus,
EWS-FLI1 might divert RBFOX2 away from the LASR
assemblies through competing phase transition processes.
Alternatively, interaction with EWS-FLI1 may modify the
affinity of RBFOX2 for its binding RNA motif. However,
on a large set of ASEs, EWS-FLI1 and RBFOX2 regu-
late alternative splicing in the same direction. This indicates
that EWS-FLI1 has ambivalent functions on RBFOX2-
regulated ASEs, which may depend on context, such as
nearby binding of additional RBPs (e.g. QKI or RBPMS)
or the exact composition of the LASR complex. In this
regard, it is interesting to mention that EWS-ETS fusion
proteins have been shown to have gain-of-function activi-
ties on some DNA target sites such as microsatellites but
also to demonstrate dominant negative action toward wild-
type ETS protein on other DNA binding sites (64,65). Even
though expression levels of wild-type ERG members are not
detected in Ewing sarcoma cells, we cannot exclude that
EWS-FLI1 may interfere with the potential splicing activity
of other members of the ETS family that may be involved
in splicing as well, beyond the ERG subfamily proteins. In
this respect, it is interesting to mention that PU1/Spi1 has
been shown to interact directly with RNA and to modulate
splicing (66).
While the idea of EWS-FLI1 influencing alternative splic-
ing was expressed almost two decades ago (12), the only
functional relevance of such a function for the Ewing sar-
coma oncogenic process was a splicing regulation of the
ARID1A gene (67). Here, we show that EWS-FLI1 inter-
feres with the function of RBFOX2, a factor that pro-
motes EMT-specific (mesenchymal) splicing programs (68).
A number of publications support a mesenchymal-stem-
cell origin for Ewing cells (52,69). Our study indicates that
the EWS-FLI1-induced reprogramming of these cells may
not only rely on transcriptional effects, in particular via
genome-wide activation of GGAA microsatellites (7,8,70)
but also on post-transcriptional effects, such as modula-
tion of the pro-mesenchymal splicing program driven by
RBFOX2. Cell-to-cell variation of the expression level of
EWS-FLI1 has been recently involved in the plasticity of
Ewing sarcoma cells (51). The hypothesis of the alteration
of splicing programs by EWS-FLI1 participating in this
plasticity process can now be thoroughly tested. Regarding
this hypothesis, we show that the EWS-FLI1-induced exon
14-containing isoform of ADD3, ADD3-L contributes to
the repression of the mesenchymal phenotype in Ewing sar-
coma cells. Specific targeting of the ADD3-L isoform leads
to an increased ability of Ewing sarcoma cells to migrate.
Further experiments are needed to decode the precise func-
tion of the ADD3 domain encoded by exon 14, especially
in the assembly of the spectrin-actin network. The observa-
tion, which needs to be confirmed on an independent series,
that high levels of the ADD3-L isoform in tumors are asso-
ciated with increased survival rates of patients, suggests that
it may constitute an interesting prognosis biomarker.
The widespread effects of wild-type ERG family proteins
on alternative splicing, that we identified in this study in
HeLa and HUVEC cells, are enriched in gene functions
that are relevant to the phenotypic effects of these pro-
teins (e.g. mitosis in HeLa cells, cell morphology and ad-
herens junctions in endothelial cells). In the future, the role
of ERG-mediated splicing regulation deserves to be inves-
tigated, in these cells as well as in additional context where
these proteins are involved (e.g. prostate cancer cells). Fi-
nally, our work suggests that alternative splicing regulation
by transcription factors may be an underappreciated phe-
nomenon.
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